Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 3
2010 1
2011 1
2012 2
2018 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Schroeder MA, Khoury HJ, Jagasia M, Ali H, Schiller GJ, Staser K, Choi J, Gehrs L, Arbushites MC, Yan Y, Langmuir P, Srinivas N, Pratta M, Perales MA, Chen YB, Meyers G, DiPersio JF. Schroeder MA, et al. Among authors: arbushites mc. Blood Adv. 2020 Apr 28;4(8):1656-1669. doi: 10.1182/bloodadvances.2019001043. Blood Adv. 2020. PMID: 32324888 Free PMC article. Clinical Trial.
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. Rugo HS, et al. Among authors: arbushites mc. Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24. Breast Cancer Res Treat. 2012. PMID: 22198412 Free PMC article. Clinical Trial.
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ. Blackwell KL, et al. Among authors: arbushites mc. Ann Oncol. 2009 Jun;20(6):1026-31. doi: 10.1093/annonc/mdn759. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179558 Free article. Clinical Trial.
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A, Press MF. Downey L, et al. Among authors: arbushites m. Clin Cancer Res. 2010 Feb 15;16(4):1281-8. doi: 10.1158/1078-0432.CCR-09-1643. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145176 Free article.
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A. Finn RS, et al. Among authors: arbushites m. J Clin Oncol. 2009 Aug 20;27(24):3908-15. doi: 10.1200/JCO.2008.18.1925. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620495 Free PMC article. Clinical Trial.
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page